Erratum: Identification of restriction factors by human genome-wide RNA interference screening of viral host range mutants exemplified by discovery of SAMD9 and WDR6 as inhibitors of the vaccinia virus K1L-C7L- mutant (mBio, (2016) 6, 4, 10.1128/mBio.01122-15);Identification of restriction factors by human genome-wide RNA interference screening of viral host range mutants exemplified by discovery of SAMD9 and WDR6 as inhibitors of the vaccinia virus k1L-C7L- mutant

mBio

Volumn 6, Issue 4, 2015, Pages

  Sivan, Gilad ^a   Ormanoglu, PinaR ^b   Buehler, Eugen C ^b   Martin, Scott E ^b,c   Moss, Bernard ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; INTERFERON REGULATORY FACTOR 1; PROTEIN VACV C7; PROTEIN VACV K1; UNCLASSIFIED DRUG; VACCINIA VIRUS PROTEIN; VIRUS PROTEIN; C7L PROTEIN, VACCINIA VIRUS; K1L PROTEIN, VACCINIA VIRUS; MEMBRANE PROTEIN; PROTEIN; SAMD9 PROTEIN, HUMAN; VIRAL PROTEIN; WDR6 PROTEIN, HUMAN;

ARTICLE; BACTERIAL GENE; BINDING AFFINITY; C7L GENE; CONTROLLED STUDY; GENE DELETION; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; K1L GENE; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN SYNTHESIS; RNA INTERFERENCE; SAMD9 GENE; VACCINIA VIRUS; VIRUS IDENTIFICATION; VIRUS REPLICATION; VIRUS TRANSMISSION; WDR6 GENE; GENETIC SCREENING; GENETICS; HELA CELL LINE; HOST PATHOGEN INTERACTION; HOST RANGE; HUMAN GENOME; IMMUNOLOGY; METABOLISM; MUTATION; PHYSIOLOGY;

GENETIC TESTING; GENOME, HUMAN; HELA CELLS; HOST SPECIFICITY; HOST-PATHOGEN INTERACTIONS; HUMANS; MEMBRANE PROTEINS; MUTATION; PROTEINS; RNA INTERFERENCE; VACCINIA VIRUS; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 84940854459     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.01735-17     Document Type: Erratum

References (34)

1. Moss B. 2013. Poxviridae, p 2129–2159. In Knipe DM, Howley PM (ed), Fields virology, 6th ed, vol 2. Lippincott Williams&Wilkins, Philadelphia, PA.
2. Upton C, Slack S, Hunter AL, Ehlers A, Roper RL. 2003. Poxvirus orthologous clusters: toward defining the minimum essential poxvirus genome. J Virol 77:7590–7600. http://dx.doi.org/10.1128/JVI.77.13.7590-7600.2003.
3. Bratke KA, McLysaght A, Rothenburg S. 2013. A survey of host range genes in poxvirus genomes. Infect Genet Evol 14:406–425. http://dx.doi.org/10.1016/j.meegid.2012.12.002.
4. Haller SL, Peng C, McFadden G, Rothenburg S. 2014. Poxviruses and the evolution of host range and virulence. Infect Genet Evol 21:15–40. http://dx.doi.org/10.1016/j.meegid.2013.10.014.
5. Gillard S, Spehner D, Drillien R, Kirn A. 1986. Localization and sequence of a vaccinia virus gene required for multiplication in human cells. Proc Natl Acad Sci U S A 83:5573–5577. http://dx.doi.org/10.1073/pnas.83.15.5573.
6. Perkus ME, Goebel SJ, Davis SW, Johnson GP, Limbach K, Norton EK, Paoletti E. 1990. Vaccinia virus host range genes. Virology 179:276–286. http://dx.doi.org/10.1016/0042-6822(90)90296-4.
7. Meng X, Jiang C, Arsenio J, Dick K, Cao J, Xiang Y. 2009. Vaccinia virus K1L and C7L inhibit antiviral activities induced by type I interferons. J Virol 83:10627–10636. http://dx.doi.org/10.1128/JVI.01260-09.
8. Drillien R, Koehren F, Kirn A. 1981. Host range deletion mutant of vaccinia virus defective in human cells. Virology 111:488–499. http://dx.doi.org/10.1016/0042-6822(81)90351-2.
9. Sutter G, Ramsey-Ewing A, Rosales R, Moss B. 1994. Stable expression of the vaccinia virus K1L gene in rabbit cells complements the host range defect of a vaccinia virus mutant. J Virol 68:4109–4116.
10. Ramsey-Ewing AL, Moss B. 1996. Complementation of a vaccinia virus host range K1L gene deletion by the non-homologous CP77 gene. Virology 222:75–86. http://dx.doi.org/10.1006/viro.1996.0399.
11. Hsiao JC, Chung CS, Drillien R, Chang W. 2004. The cowpox virus host range gene, CP77, affects phosphorylation of eIF2 alpha and vaccinia viral translation in apoptotic HeLa cells. Virology 329:199–212. http://dx.doi.org/10.1016/j.virol.2004.07.032.
12. Backes S, Sperling KM, Zwilling J, Gasteiger G, Ludwig H, Kremmer E, Schwantes A, Staib C, Sutter G. 2010. Viral host-range factor C7 or K1 is essential for modified vaccinia virus Ankara late gene expression in human and murine cells, irrespective of their capacity to inhibit protein kinase R-mediated phosphorylation of eukaryotic translation initiation factor 2 alpha. J Gen Virol 91:470–482. http://dx.doi.org/10.1099/vir.0.015347-0.
13. Liu J, Rothenburg S, McFadden G. 2012. The poxvirus C7L host range factor superfamily. Curr Opin Virol 2:764–772. http://dx.doi.org/10.1016/j.coviro.2012.09.012.
14. Meng XZ, Chao J, Xiang Y. 2008. Identification from diverse mammalian poxviruses of host-range regulatory genes functioning equivalently to vaccinia virus C7L. Virology 372:372–383. http://dx.doi.org/10.1016/j.virol.2007.10.023.
15. Liu J, Wennier S, Zhang LL, McFadden G. 2011. M062 is a host range factor essential for myxoma virus pathogenesis and functions as an antagonist of host SAMD9 in human cells. J Virol 85:3270–3282. http://dx.doi.org/10.1128/JVI.02243-10.
16. Bradley RR, Terajima M. 2005. Vaccinia virus K1L protein mediates host-range function in RK-13 cells via ankyrin repeat and may interact with a cellular GTPase-activating protein. Virus Res 114:104–112. http://dx.doi.org/10.1016/j.virusres.2005.06.003.
17. Meng XZ, Xiang Y. 2006. Vaccinia virus K1L protein supports viral replication in human and rabbit cells through a cell-type-specific set of its ankyrin repeat residues that are distinct from its binding site for ACAP2. Virology 353:220–233. http://dx.doi.org/10.1016/j.virol.2006.05.032.
18. Li YC, Meng XZ, Xiang Y, Deng JP. 2010. Structure function studies of vaccinia virus host range protein K1 reveal a novel functional surface for ankyrin repeat proteins. J Virol 84:3331–3338. http://dx.doi.org/10.1128/JVI.02332-09.
19. Shisler JL, Jin XL. 2004. The vaccinia virus K1L gene product inhibits host NF-kB activation by preventing IkBa degradation. J Virol 78:3553–3560. http://dx.doi.org/10.1128/JVI.78.7.3553-3560.2004.
20. Willis KL, Patel S, Xiang Y, Shisler JL. 2009. The effect of the vaccinia K1 protein on the PKR-eIF2 alpha pathway in RK13 and HeLa cells. Virology 394:73–81. http://dx.doi.org/10.1016/j.virol.2009.08.020.
21. Meng XZ, Schoggins J, Rose L, Cao JX, Ploss A, Rice CM, Xiang Y. 2012. C7L family of poxvirus host range genes inhibits antiviral activities induced by type I interferons and interferon regulatory factor 1. J Virol 86:4538–4547. http://dx.doi.org/10.1128/JVI.06140-11.
22. Liu J, McFadden G. 2015. SAMD9 is an innate antiviral host factor with stress response properties that can be antagonized by poxviruses. J Virol 89:1925–1931. http://dx.doi.org/10.1128/JVI.02262-14.
23. König R, Chiang C, Tu BP, Yan SF, DeJesus PD, Romero A, Bergauer T, Orth A, Krueger U, Zhou Y, Chanda SK. 2007. A probability-based approach for the analysis of large-scale RNAi screens. Nat Methods 4:847–849. http://dx.doi.org/10.1038/nmeth1089.
24. Sivan G, Martin SE, Myers TG, Buehler E, Szymczyk KH, Ormanoglu P, Moss B. 2013. Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. Proc Natl Acad Sci U S A 110:3519–3524. http://dx.doi.org/10.1073/pnas.1300708110.
25. Fuerst TR, Niles EG, Studier FW, Moss B. 1986. Eukaryotic transientexpression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc Natl Acad Sci U S A 83: 8122–8126. http://dx.doi.org/10.1073/pnas.83.21.8122.
26. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, Rice CM. 2011. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472:481–485. http://dx.doi.org/10.1038/nature09907.
27. Lemos de Matos A, Liu J, McFadden G, Esteves PJ. 2013. Evolution and divergence of the mammalian SAMD9/SAMD9L gene family. BMC Evol Biol 13:121. http://dx.doi.org/10.1186/1471-2148-13-121.
28. Chefetz I, Ben Amitai D, Browning S, Skorecki K, Adir N, Thomas MG, Kogleck L, Topaz O, Indelman M, Uitto J, Richard G, Bradman N, Sprecher E. 2008. Normophosphatemic familial tumoral calcinosis is caused by deleterious mutations in SAMD9, encoding a TNF-alpha responsive protein. J Invest Dermatol 128:1423–1429. http://dx.doi.org/10.1038/sj.jid.5701203.
29. Tanaka M, Shimbo T, Kikuchi Y, Matsuda M, Kaneda Y. 2010. Sterile alpha motif containing domain 9 is involved in death signaling of malignant glioma treated with inactivated Sendai virus particle (HVJ-E) or type I interferon. Int J Cancer 126:1982–1991. http://dx.doi.org/10.1002/ijc.24965.
30. Hershkovitz D, Gross Y, Nahum S, Yehezkel S, Sarig O, Uitto J, Sprecher E. 2011. Functional characterization of SAMD9, a protein deficient in normophosphatemic familial tumoral calcinosis. J Invest Dermatol 131:662–669. http://dx.doi.org/10.1038/jid.2010.387.
31. Topaz O, Indelman M, Chefetz I, Geiger D, Metzker A, Altschuler Y, Choder M, Bercovich D, Uitto J, Bergman R, Richard G, Sprecher E. 2006. A deleterious mutation in SAMD9 causes normophosphatemic familial tumoral calcinosis. Am J Hum Genet 79:759–764. http://dx.doi.org/10.1086/508069.
32. Li D, Burch P, Gonzalez O, Kashork CD, Shaffer LG, Bachinski LL, Roberts R. 2000. Molecular cloning, expression analysis, and chromosome mapping of WDR6, a novel human WD-repeat gene. Biochem Biophys Res Commun 274:117–123. http://dx.doi.org/10.1006/bbrc.2000.3012.
33. Xie X, Wang Z, Chen Y. 2007. Association of LKB1 with a WD-repeat protein WDR6 is implicated in cell growth arrest and p27Kip1 induction. Mol Cell Biochem 301:115–122. http://dx.doi.org/10.1007/s11010-006-9402-5.
34. Chiba T, Inoue D, Mizuno A, Komatsu T, Fujita S, Kubota H, Luisa Tagliaro M, Park S, Trindade LS, Hayashida T, Hayashi H, Yamaza H, Higami Y, Shimokawa I. 2009. Identification and characterization of an insulin receptor substrate 4-interacting protein in rat brain: implications for longevity. Neurobiol Aging 30:474–482. http://dx.doi.org/10.1016/j.neurobiolaging.2007.07.008.